Nipa1 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
NIPA1 (Non-imprinted in Prader-Willi/Angelman Syndrome 1) encodes a magnesium transporter protein that plays critical roles in neuronal function, synaptic transmission, and intracellular magnesium homeostasis. Mutations in NIPA1 are primarily associated with hereditary spastic paraplegia (HSP), but emerging research suggests potential roles in broader neurodegenerative processes including Alzheimer's disease (AD) and Parkinson's disease (PD). [1]
| Non-imprinted in Prader-Willi/Angelman Syndrome 1 | |
|---|---|
| Gene Symbol | NIPA1 |
| Full Name | Magnesium Transporter NIPA1 |
| Chromosome | 9q21.13 |
| NCBI Gene ID | [64359](https://www.ncbi.nlm.nih.gov/gene/64359) |
| OMIM | [608456](https://www.omim.org/entry/608456) |
| Ensembl ID | ENSG00000139970 |
| UniProt ID | [Q9BUE2](https://www.uniprot.org/uniprot/Q9BUE2) |
| Protein Class | Magnesium transporter (SLC family) |
| Associated Diseases | Hereditary Spastic Paraplegia Type 6 (SPG6) |
NIPA1 is a 317-amino acid transmembrane protein belonging to the SLC41A family of magnesium transporters[1]. The protein contains 9-10 transmembrane domains and localizes primarily to the plasma membrane and endolysosomal compartments. Its structure includes a conserved magnesium transporter domain that facilitates Mg²⁺ ion flux across cellular membranes.
NIPA1 functions as a Mg²⁺ ion channel with the following characteristics:
The transporter maintains intracellular magnesium homeostasis, which is critical for:
NIPA1 exhibits widespread expression throughout the central nervous system with highest levels in:
In neurons, NIPA1 localizes to:
During neurodevelopment, NIPA1 regulates:
At the synapse, NIPA1 modulates:
Proper intracellular Mg²⁺ levels are essential for:
Pathogenesis: Dominant NIPA1 mutations cause SPG6, characterized by progressive lower limb spasticity and weakness[2].
| Feature | Description |
|---|---|
| Inheritance | Autosomal dominant |
| Onset | Variable (adolescence to adulthood) |
| Core Symptoms | Lower limb spasticity, weakness, urinary urgency |
| Additional Features | Variable peripheral neuropathy, cognitive impairment |
Mechanism: Mutant NIPA1 proteins exhibit reduced magnesium transport activity, leading to:
Emerging evidence links NIPA1 to AD pathogenesis:
NIPA1 involvement in PD includes:
Pharmaceutical development focuses on:
Future therapeutic strategies include:
NIPA1 is a critical magnesium transporter with essential roles in neuronal function and survival. While primarily associated with hereditary spastic paraplegia, emerging research reveals broader implications for neurodegenerative diseases including AD, PD, and ALS. Understanding NIPA1 function and developing therapeutic modulators represents a promising avenue for treating disorders of neuronal magnesium homeostasis.
Nipa1 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Nipa1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.